Introduction:

Dear colleagues,

Thank you very much for participating in this survey about sustainability of human research biobanks. It will take about 15 minutes to fill out.

This is a worldwide survey. We are approaching you via multiple channels and you might get the same invitation and link, respectively from different sources. Please fill out only one survey. However you might forward the link for the survey to other biobankers you know.

We conducted a pilot survey which was recently published (Simeon-Dubach D, Goldring K, Henderson MK. Trends in Biobanking Business Planning: Initial Results of a Survey of Biobankers. Biopreserv Biobank 2017;15:72-74).

 

Please note some definitions we use in this survey

Research biobank:

This survey focuses on sustainability of research biobanks. The purpose of the material and data stored in your biobank should be for biomedical research only and not for therapeutic or diagnostic purpose. If you store both categories of material please only take the research part into account when answering the questions.

 

Biospecimens, samples and aliquots:

A (bio) specimen is what is collected and transferred to the biobank (a patient / donor can donate multiple (bio)specimens at multiple times). In the biobank a (bio)specimen can be processed and aliquoted. The sample / aliquot is the uniquely traced item in your biobank inventory system. The output from the biobank is a sample or an aliquot.

 

At the end of the survey we will ask you for your email. This is voluntary and might only be helpful if we have some further questions.

If you want to get in touch with us please write an email to kirstin.goldring@astrazeneca.com (Kirstin Goldring), hendersm@mail.nih.gov (Marianne Henderson) or biobanking@medservice.ch (Daniel Simeon-Dubach).

We want to thank you very much for your collaboration. We are planning to publish the results of this survey later this year.

 
10% of survey complete.

T